Login to Your Account

Clinic Roundup

Monday, February 27, 2012

• CSL Behring LLC, of King of Prussia, Pa., said the first patient was screened in its recombinant coagulation single-chain Factor VIII trial in hemophilia A. The study is part of the AFFINITY Phase I/II trial program, which is testing crossover safety, efficacy and pharmacokinetics of the product compared to recombinant human antihemophilic Factor VIII (octocog alpha).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription